Eyenovia’s (EYEN) Neutral Rating Reiterated at LADENBURG THALM/SH SH

Eyenovia (NASDAQ:EYEN)‘s stock had its “neutral” rating restated by equities research analysts at LADENBURG THALM/SH SH in a research note issued to investors on Monday,Benzinga reports.

A number of other equities analysts have also recently commented on the company. Brookline Capital Management reissued a “hold” rating on shares of Eyenovia in a report on Friday. HC Wainwright cut Eyenovia from a “buy” rating to a “neutral” rating and cut their price target for the company from $12.00 to $2.00 in a report on Monday. Finally, William Blair reiterated a “market perform” rating on shares of Eyenovia in a report on Friday.

Eyenovia Stock Performance

NASDAQ EYEN traded up $0.01 on Monday, hitting $0.11. 8,947,495 shares of the company’s stock traded hands, compared to its average volume of 1,481,186. The firm has a market capitalization of $7.06 million, a PE ratio of -0.15 and a beta of 1.75. Eyenovia has a 1-year low of $0.09 and a 1-year high of $2.57. The firm’s 50-day moving average price is $0.49 and its two-hundred day moving average price is $0.71. The company has a current ratio of 0.74, a quick ratio of 0.27 and a debt-to-equity ratio of 0.58.

Eyenovia (NASDAQ:EYEN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter in the prior year, the company posted ($0.18) EPS. As a group, analysts expect that Eyenovia will post -0.5 EPS for the current year.

Insider Transactions at Eyenovia

In other Eyenovia news, CEO Michael M. Rowe purchased 50,000 shares of the stock in a transaction dated Monday, August 26th. The stock was acquired at an average cost of $0.57 per share, for a total transaction of $28,500.00. Following the acquisition, the chief executive officer now owns 82,927 shares in the company, valued at $47,268.39. This trade represents a 151.85 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.10% of the company’s stock.

Institutional Investors Weigh In On Eyenovia

A number of institutional investors have recently made changes to their positions in EYEN. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Eyenovia in the 2nd quarter valued at approximately $26,000. Ground Swell Capital LLC purchased a new position in Eyenovia during the 2nd quarter valued at about $27,000. Nations Financial Group Inc. IA ADV grew its position in Eyenovia by 24.4% in the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock valued at $30,000 after acquiring an additional 10,000 shares in the last quarter. Financial Management Network Inc. acquired a new position in Eyenovia in the 3rd quarter valued at about $39,000. Finally, SkyView Investment Advisors LLC purchased a new stake in Eyenovia during the second quarter worth about $87,000. 25.84% of the stock is currently owned by institutional investors and hedge funds.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.